financetom
Business
financetom
/
Business
/
Polycab India Q3 results: Net profit flat to Rs 248 crore, revenue up 23%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Polycab India Q3 results: Net profit flat to Rs 248 crore, revenue up 23%
Jan 21, 2022 10:20 AM

Polycab India, a leading manufacturer of wires and cables, on Friday, reported a 1.36 percent year-on-year (YoY) rise in net profit at Rs 248.37 crore for the third quarter ended December 31, 2021.

In the corresponding quarter last year, the company posted a net profit of Rs 245.02 crore. Its revenue from operations grew 22.78 percent to Rs 3,371.99 crore, compared with Rs 2,746.34 crore in the year-ago period.

The earnings before interest, taxes, depreciation and amortization (EBITDA) margin continued to improve sequentially by 100bps to 10.7 percent led by price hikes and better operating leverage, partly offset by input cost pressures and higher A&P spends. PAT margin improved to 7.4 percent against the previous quarter. PAT grew 1 percent YoY.

Also Read:

JSW Steel Q3 results: Net profit jumps 69.2% YoY to Rs 4,516 crore, misses estimates

Inder T. Jaisinghani, chairman and managing director, Polycab India Ltd, said, "We saw the momentum continue in 3Q despite a challenging business environment. We recorded the highest quarterly top-line in the history of the company for the second consecutive quarter which substantiates our strategy to be agile, focus on robust execution and consistently deliver the best quality of products to our customers."

"We have revitalised our demand generation capabilities and Go-To-Market strategy with greater emphasis on Emerging India clusters and new age channels. We have also commenced work on developing a robust ESG framework that will align us to the best of global standards and serve as guiding principles for sustainable business practices."

The results came after the close of the market hours. Shares of Polycab India ended at Rs 2,510.30, down by Rs 171.70, or 6.40 percent on the BSE.

Also Read: L&T Finance Q3 Results: net profit up 46% QoQ to Rs 326 crore; rural lending now largest segment

(Edited by : Jomy Jos Pullokaran)

First Published:Jan 21, 2022 7:20 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tequila giant Becle sees 2024 net sales growth in low single digits
Tequila giant Becle sees 2024 net sales growth in low single digits
Oct 24, 2024
MEXICO CITY, Oct 24 (Reuters) - Mexican distiller Becle , the world's largest tequila maker, sees 2024 net sales growth in the low single digits at a constant currency rate, Chief Financial Officer Rodrigo de la Maza said on a conference call on Thursday. ...
Update: Whirlpool Shares Rise After Q3 Results, Guidance Reaffirmed
Update: Whirlpool Shares Rise After Q3 Results, Guidance Reaffirmed
Oct 25, 2024
12:33 PM EDT, 10/24/2024 (MT Newswires) -- (Updates with the latest stock move in the first paragraph and headline.) Whirlpool (WHR) shares were up more than 13% in recent Thursday trading after the company reaffirmed its 2024 guidance with its Q3 results. Late Wednesday, the company reported Q3 adjusted earnings of $3.43 per diluted share, down from $5.45 a year...
AbbVie's Emraclidine Phase 2 Trial Data in Q4 Present Major Catalyst, UBS Says
AbbVie's Emraclidine Phase 2 Trial Data in Q4 Present Major Catalyst, UBS Says
Oct 24, 2024
11:47 AM EDT, 10/24/2024 (MT Newswires) -- AbbVie's ( ABBV ) expected Q4 report on its phase 2 Empower 1 and 2 studies of emraclidine in schizophrenia will be a major catalyst, UBS said in a note to clients Thursday. UBS said that due to the need for new schizophrenia treatments, a statistically significant benefit across both trials should be...
3 Health Care Stocks Moving In Thursday's Intraday Session
3 Health Care Stocks Moving In Thursday's Intraday Session
Oct 25, 2024
Gainers Viking Therapeutics ( VKTX ) stock moved upwards by 22.8% to $74.16 during Thursday's regular session. The company's market cap stands at $8.2 billion. As per the news, the Q3 earnings report came out yesterday. Losers Intellia Therapeutics ( NTLA ) stock declined by 18.3% to $16.29 during Thursday's regular session. The market value of their outstanding shares is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved